Last reviewed 2026-04-19 · How we verify

CAMOSTAT

CAMOSTAT works by blocking the activity of hepsin, a protease that contributes to inflammation and tissue damage.

CAMOSTAT is a small molecule drug in the camostat class, originally developed by and currently owned by . It targets the serine protease hepsin and is used to treat gastro-esophageal reflux disease with esophagitis. The commercial status of CAMOSTAT is unknown, and it is not FDA-approved. Key safety considerations are not well-documented. CAMOSTAT works by inhibiting the activity of hepsin, a protease involved in inflammation and tissue damage.

At a glance

Mechanism of action

Think of CAMOSTAT like a key that locks up a specific enzyme, called hepsin, which is involved in the breakdown of tissues and the promotion of inflammation. By blocking hepsin, CAMOSTAT helps to reduce inflammation and tissue damage, which can help to alleviate symptoms of gastro-esophageal reflux disease with esophagitis. This can lead to improved healing and reduced discomfort for patients.

Approved indications

• Gastro-esophageal reflux disease with esophagitis

Common side effects

No common side effects on file.

Key clinical trials

• The Impact of Camostat Mesilate on COVID-19 Infection (PHASE1,PHASE2)
• Effect Camostat for Kidney Protection in Chronic Kidney Disease (PHASE2)
• Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation (PHASE2)
• Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 (PHASE2)
• The Potential of Camostat in COVID-19 (PHASE2)
• ACTIV-2: A Study for Outpatients With COVID-19 (PHASE2,PHASE3)
• Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects (PHASE1)
• A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.